Lisa A. Carey

Cancer Research · 2005–2022

A researcher in the Science corpus: 17 papers; trusts 2 researchers and is trusted by 3 researchers here, as inferred from the citation graph.

Subfields

• Cancer Research — 202 citations into it; #1,055 of 1,780 by trust here, #482 by citations
• Molecular Biology — 74 citations into it

Whom Lisa A. Carey trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Charles M. Perou
2. Alan Ashworth
3. N. Turner
4. Andrew Tutt
5. W. Foulkes
6. Robert Tibshirani

Who trusts Lisa A. Carey overall

1. Aleix Prat
2. J. Reis-Filho
3. K. J. Chavez
4. Charles M. Perou
5. Anurag Singh

Papers from Lisa A. Carey's perspective

Ordered by how strongly the researchers Lisa A. Carey trusts endorse each paper. Same corpus, a different order for every researcher.

1. Molecular portraits of human breast tumours (Nature)
2. Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma (Clinical Cancer Research)
3. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. (Journal of the American Medical Association (JAMA))
4. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer (Archives of Pathology & Laboratory Medicine)
5. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors (Genome Biology)
6. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. (Cancer Research)
7. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. (Journal of the National Cancer Institute)
8. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. (New England Journal of Medicine)
9. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (New England Journal of Medicine)
10. A gene-expression signature as a predictor of survival in breast cancer. (New England Journal of Medicine)

Their papers

• Molecular classification and molecular forecasting of breast cancer: ready for clinical application? (2005) — 970 citations
• Triple negative breast cancer: Pitfalls and progress (2022) — 678 citations
• Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline (2021) — 788 citations
• Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 (2021) — 687 citations
• Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer. (2021)
• Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer (2021)
• Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. (2020) — 1,200 citations
• Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. (2019) — 1,055 citations
• 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† (2018) — 1,021 citations
• De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (2018) — 862 citations
• 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). (2017) — 674 citations
• Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). (2015) — 867 citations
• Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer (2013) — 630 citations
• Triple-negative breast cancer: disease entity or title of convenience? (2010) — 790 citations
• Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast Cancer (2009) — 621 citations
• Epidemiology of basal-like breast cancer (2008) — 840 citations
• The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes (2007) — 2,077 citations